Hui Shao,
Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 294-8323
Business Email:
hui.shao@ufl.edu
Teaching Profile
Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2021-2023
PHA6940 Supervised Teaching
2021-2023
PHA6971 Research for Master’s Thesis
2020-2023
PHA6935 Selected Topics in Pharmacy
2020-2023
PHA6910 Supervised Research
2021-2023
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2020-2023
PHA7979 Advanced Research
2021-2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2022
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2022
PHA6937 Topics in Pharmaceutical Administration
2020-2021
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-4088-546X
Publications
2023
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in
US
adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism.
25(2):516-525
[DOI] 10.1111/dom.14894.
[PMID] 36251173.
2023
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Annals of Internal Medicine.
[DOI] 10.7326/m22-3051.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care.
45(11):e161-e162
[DOI] 10.2337/dc22-1230.
[PMID] 36099174.
2022
Predicting incident heart failure among patients with type 2 diabetes mellitus: The
DM‐CURE
risk score
Diabetes, Obesity and Metabolism.
24(11):2203-2211
[DOI] 10.1111/dom.14806.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care.
45(8):1814-1821
[DOI] 10.2337/dc21-2601.
[PMID] 35700384.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care.
45(2):e32-e33
[DOI] 10.2337/dc21-1800.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care.
44(10):e180-e182
[DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care.
44(4):925-934
[DOI] 10.2337/dc20-2871.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care.
43(2):e25-e25
[DOI] 10.2337/dc19-1891.
[PMID] 31959647.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care.
43(10):2396-2402
[DOI] 10.2337/dc19-2273.
[PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care.
43(11):2847-2852
[DOI] 10.2337/dc20-0465.
[PMID] 32887705.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care.
43(7):1530-1536
[DOI] 10.2337/dc20-0227.
[PMID] 32345650.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care.
42(11):2136-2142
[DOI] 10.2337/dc19-0381.
Grants
Sep 2022
– Dec 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
– Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
– Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020
– Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV
via SANOFI
Jun 2020
– Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Contact Details
Phones:
- Business:
- (352) 294-8323
Emails:
- Business:
- hui.shao@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100496
GAINESVILLE FL 32610
Recent news
Dr. Hui Shao elected Director of Academics for the China Health Policy and Management Society
As Director of Academics, Shao will organize CHPAMS’ annual conference and develop two webinar series focused on introducing advanced methods in health economics and health services research and issues-driven research…
Dr. Hui Shao earns Early Career Award from CDC
The Centers for Disease Control and Prevention, or CDC, Health Economics Research Group bestowed Hui Shao, M.D., Ph.D., an assistant professor of pharmaceutical outcomes and policy, with the Kaafee Billah…